Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study
- Potential Cost-Effectiveness of a New Infant Tuberculosis Vaccine in South Africa - Implications for Clinical Trials: A Decision Analysis. Ditkowsky, Jared B.; Schwartzman, Kevin // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1
Novel tuberculosis vaccines are in varying stages of pre-clinical and clinical development. This study seeks to estimate the potential cost-effectiveness of a BCG booster vaccine, while accounting for costs of large-scale clinical trials, using the MVA85A vaccine as a case study for estimating...
- `Poor' vaccine ruled out in TB puzzle. Day, Michael // New Scientist;7/13/96, Vol. 151 Issue 2038, p14
Reports on a British study designed to explain why the BCG vaccine often fails to protect against tuberculosis (TB) in developing countries. Rejection of notion that poor quality of vaccines render the TB treatment ineffective; Exposure of children in tropical countries to numerous other...
- Improving vaccines against tuberculosis. Britton, Warwick J; Palendira, Umaimainthan // Immunology & Cell Biology;Feb2003, Vol. 81 Issue 1, p34
Summary Tuberculosis remains a major cause of mortality and physical and economic deprivation worldwide. There have been significant recent advances in our understanding of the Mycobacterium tuberculosis genome, mycobacterial genetics and the host determinants of protective immunity....
- TB vaccine failure was predictable. Beverley, Peter // Nature;11/28/2013, Vol. 503 Issue 7477, p469
A letter to the editor is presented related to the role of the MVA85A vaccine, a tuberculosis (TB) vaccine, in the protection of TB over the Bacillus Calmetteâ€“GuÃ©rin (BCG) vaccine.
- Editorial Response: Variation in Clinical and Immune Responses to Bacille Calmette-Guerin--Implications for an Improved Tuberculosis Vaccine. // Clinical Infectious Diseases;4/1/1999, Vol. 28 Issue 4, p791
Comments on an article about the variation in clinical and immune responses to the tuberculosis vaccine bacille Calmette-Gu Ã© rin. Concerns on the effectiveness of the vaccine; Observations on the duration of vaccine-induced ulceration; Need for further study to determine the limitations of...
- BCG in Britain. // British Medical Journal;9/27/1980, Vol. 281 Issue 6244, p825
Assesses the efficacy of BCG vaccination in treating tuberculosis in Great Britain. Mode of transmission of tuberculosis; Reduction in the incidence of tuberculosis; Complications of BCG vaccination.
- BCG campaign may be delayed. // Pulse;8/19/2002, Vol. 62 Issue 32, p8
Reports on the possible delay of the start of the BCG school vaccination campaign in Great Britain due in October 2002, following the withdrawal of the only tuberculosis vaccine approved in the country.
- New TB vaccination programme. // Practice Nurse;7/29/2005, Vol. 30 Issue 2, p7
This article reports that the British government will replace the universal BCG vaccination program with a program of targeted vaccination for individuals that have the greatest risk.
- Addressing your patients' concerns on BCG vaccine. Baxter, David // Pulse;10/21/2002, Vol. 62 Issue 40, p59
Reports on the withdrawal of Bacille Calmette Guerin (BCG) tuberculosis (TB) vaccine in Great Britain. Background on the BCG vaccine; Reasons for the withdrawal of the TB vaccine from the market; Role of TB vaccines in the control of tuberculosis in England and Wales; Tips for general practice...